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Whole genome characterization of the mechanisms of daptomycin resistance in 
clinical and laboratory derived isolates of Staphylococcus aureus 
Abstract 
Background 
Daptomycin remains one of our last-line anti-staphylococcal agents. This study aims to characterize the 
genetic evolution to daptomycin resistance in S. aureus. 
Methods 
Whole genome sequencing was performed on a unique collection of isogenic, clinical (21 strains) and 
laboratory (12 strains) derived strains that had been exposed to daptomycin and developed daptomycin-
nonsusceptibility. Electron microscopy (EM) and lipid membrane studies were performed on selected 
isolates. 
Results 
On average, six coding region mutations were observed across the genome in the clinical daptomycin 
exposed strains, whereas only two mutations on average were seen in the laboratory exposed pairs. All 
daptomycin-nonsusceptible strains had a mutation in a phospholipid biosynthesis gene. This included 
mutations in the previously described mprF gene, but also in other phospholipid biosynthesis genes, 
including cardiolipin synthase (cls2) and CDP-diacylglycerol-glycerol-3-phosphate 
3-phosphatidyltransferase (pgsA). EM and lipid membrane composition analyses on two clinical pairs 
showed that the daptomycin-nonsusceptible strains had a thicker cell wall and an increase in membrane 
lysyl-phosphatidylglycerol. 
Conclusion 
Point mutations in genes coding for membrane phospholipids are associated with the development of 
reduced susceptibility to daptomycin in S. aureus. Mutations in cls2 and pgsA appear to be new genetic 
mechanisms affecting daptomycin susceptibility in S. aureus. 
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Abstract 
Background
Daptomycin remains one of our last-line anti-staphylococcal agents. This study aims to 
characterize the genetic evolution to daptomycin resistance in S. aureus.
Methods
Whole genome sequencing was performed on a unique collection of isogenic, clinical (21 strains) 
and laboratory (12 strains) derived strains that had been exposed to daptomycin and developed 
daptomycin-nonsusceptibility. Electron microscopy (EM) and lipid membrane studies were 
performed on selected isolates.
Results
On average, six coding region mutations were observed across the genome in the clinical 
daptomycin exposed strains, whereas only two mutations on average were seen in the 
laboratory exposed pairs. All daptomycin-nonsusceptible strains had a mutation in a 
phospholipid biosynthesis gene. This included mutations in the previously described mprF gene, 
but also in other phospholipid biosynthesis genes, including cardiolipin synthase (cls2) and CDP-
diacylglycerol-glycerol-3-phosphate 3-phosphatidyltransferase (pgsA). EM and lipid membrane 
composition analyses on two clinical pairs showed that the daptomycin-nonsusceptible strains 
had a thicker cell wall and an increase in membrane lysyl-phosphatidylglycerol.
Conclusion
Point mutations in genes coding for membrane phospholipids are associated with the 
development of reduced susceptibility to daptomycin in S. aureus. Mutations in cls2 and pgsA 
appear to be new genetic mechanisms affecting daptomycin susceptibility in S. aureus.
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INTRODUCTION 
Staphylococcus aureus is one of the most significant human bacterial pathogens, causing immense 
morbidity and mortality in hospitalised patients, as well as in the community. It causes a diverse 
range of clinical disease, with mortality from infection reported as high as 35% [1]. Compounding 
this severity of disease is the constant adaptation of the bacteria to antibiotic pressure, with the 
emergence of resistance in S. aureus now being one of the most important public health problems 
in the developed world. As a consequence of this resistance, reliance on ‘last-line’ anti-
staphylococcal agents such as vancomycin, linezolid, and daptomycin has increased dramatically 
over recent years, and unfortunately, reduced susceptibility to these agents has also been described 
[2], [3].
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Daptomycin is a cyclic lipopeptide antibiotic that has recently been FDA approved for the treatment 
of complicated skin and soft tissue infections, and S. aureus bacteremia with or without right-sided 
endocarditis [2]. Understanding the mechanism of action of daptomycin has remained challenging, 
but current evidence indicates that it interacts with the bacterial cytoplasmic membrane in a 
calcium-dependent manner, leading to potassium efflux and membrane depolarisation, with 
subsequent cell death [4], [5]. Using model membranes, it has been shown that negatively charged 
lipids in the presence of calcium allow daptomycin to insert and perturb bilayer membranes [4]. 
Importantly, the majority of S. aureus membrane lipids are comprised of negatively charged 
phospholipids: phosphatidylglycerol (PG) and cardiolipin [4].
Therapeutic failures with daptomycin for infections due to S. aureus have now been reported, with 
many of these being associated with the evolution of reduced susceptibility to daptomycin in the 
setting of deep-seated and poorly controlled infection [2], [6], [7], [8]. The mechanisms of 
daptomycin resistance in S. aureus have focused on the role of the staphylococcal membrane 
protein, MprF. MprF is a bifunctional protein that mediates both the lysinylation of PG and its 
translocation to the outer leaflet of the membrane [9]. Point mutations within MprF have been 
described in S. aureus strains with reduced susceptibility to daptomycin, and such mutations appear 
to cause a gain-in-function, hypothesized to result in accelerated membrane translocation of Lysyl-
PG (L-PG), thereby resulting in a reduced net-negative membrane charge that may electrostatically 
repel calcium-complexed daptomycin [10]. Other mutations that have been reported include 
mutations in walK (previously yycG), which encodes a sensor histidine kinase that regulates cell 
wall metabolism and virulence, and a point mutation in each of rpoB and rpoC, encoding subunits of 
RNA polymerase [11]. Furthermore, increased expression of the dltABCD operon, which is 
responsible for D-alanylating wall teichoic acids and contributes to the net-positive surface charge, 
has been shown to be associated with reduced susceptibility to daptomycin [10]. Thus far, the 
study of the genetic mechanisms of daptomycin resistance have been limited to analyses of single 
pairs of isolates or isolates that are laboratory derived [11], [12], [13], [14].
To elucidate the genetic factors involved in the evolution of reduced susceptibility to daptomycin in 
S. aureus, we performed whole genome sequencing of 33 carefully selected strains, which included 
nine clinical isogenic pairs or series (21 strains) and nine laboratory derived mutants from three 
parent strains (12 strains). We identified previously described mutations associated with 
daptomycin resistance such as mprF, walK and rpoB but most importantly, we identified novel 
mutations in two genes responsible for the production of the anionic membrane phospholipids, PG 
and cardiolipin. In select clinical pairs, these mutations were associated with changes in 
phospholipid membrane composition that would explain a reduced affinity for daptomycin, and 
changes in cell wall thickness. This study represents the first large-scale comparative assessment of 
genome-wide factors involved in daptomycin-nonsusceptibility in staphylococci derived from active 
clinical infections.
METHODS 
Ethics Statement
The clinical S. aureus isolates used in this study were referred to our laboratory due to persistence 
during daptomycin therapy. Ethics approval was not required for this laboratory study, as no patient 
identifiers or clinical details apart from the site where the culture was taken (eg blood, bone or 
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heart valve) was obtained. As referenced in Table 1, some of the strains were from previously 
published work and some of these publications contain clinical information.
Table 1. Characteristics of the daptomycin
-exposed clinical strains of Staphylococcus 
aureus used in this study.
doi:10.1371/journal.pone.0028316.t001
• Download: PowerPoint slide | larger image (78KB PNG) | original image (402KB TIFF) 
Bacterial strains and culture conditions
Isolates obtained from the same patient were previously confirmed to be isogenic based on pulsed-
field gel electrophoresis. All bacteria were stored at −80°C until further testing. Daptomycin 
(Cubist, MA) susceptibility testing was performed by broth macrodilution using cation-adjusted 
Mueller-Hinton II broth (BD) supplemented to contain a final calcium concentration of 50 µg/ml. To 
determine the differences between in vivo and in vitro daptomycin exposure on the genetic 
evolution to resistance, three reference S. aureus strains underwent in vitro daptomycin exposure. 
A prototype hospital-acquired MRSA strain was selected (MRSA32 [A5948]), as well as an agr+ 
(RN6607 [A8115]) and its isogenic agr− mutant strain (RN9120 [A8117]). The latter two strains 
also enabled an assessment of the effect of agr on daptomycin resistance. In vitro daptomycin 
exposure was performed in Brain Heart Infusion (BHI) broth using a high bacterial inoculum (108 
CFU/ml) and 48 hour exposure to daptomycin at a concentration of 8 µg/ml at 35°C. The culture 
was then plated onto agar containing varying concentrations of daptomycin, and single colonies 
were chosen for formal susceptibility testing. Three independent mutants from each reference strain 
were selected for sequencing. One of the mutants from A5948 was generated previously (A6658) 
[15].
Whole genome sequencing
Genomic DNA was extracted according to manufacturer's guidelines (Promega Wizard Genomic Kit). 
All daptomycin-susceptible parent genomes were sequenced using 454 FLX pyrosequencing (Roche) 
with DNA fragment libraries according to the manufacturer's recommendations. Genomes were 
assembled using Newbler and the runAssembly script was then used to assemble reads into contigs. 
To remove contaminating sequences, final assemblies were BLASTed to the NCBI non-redundant 
(NR) database and UniVecCore. Assembly annotation was performed using a combination of ab 
initio and evidence-based approaches. For further details see supplementary material (Text S1). A 
summary of gene finding data for each locus can be viewed at the Broad Institute S. aureus Drug 
Resistance Project group database 
(http://www.broadinstitute.org/annotation /genome/staphylococcus_aureus_drug_resis tance/).
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Single Nucleotide Polymorphism (SNP) and Phylogenetic Analysis
The daptomycin-nonsusceptible daughter strains were sequenced to high coverage (≥100 fold) with 
76 nucleotide reads produced on the Illumina platform. The reads were used to call SNPs against 
the parent assemblies using the variant ascertainment algorithm (VAAL), a polymorphism discovery 
algorithm for short reads developed by the Broad Institute [16]. Select SNPs were confirmed 
independently using PCR sequencing. Phylogenetic analysis was performed using single-copy core 
gene trees that were generated from orthologous groups computed by orthoMCL 
(http://www.orthomcl.org/cgi-bin/OrthoMcl Web.cgi) [17]. An all versus all BLAST was performed 
using the predicted protein sequence from all genomes of interest. All BLAST hits with an e-
value<1e−5 were used as input to orthoMCL. To generate trees, nucleotide sequences for all single-
copy core genes were retrieved and aligned by orthologous group [18]. These alignments were 
trimmed using trimAL to allow concatenation [19]. Aligned, trimmed and concatenated sequences 
were then used to build trees using FastTree [20]. Using the genome sequence for all parent 
strains, multi-locus sequence types (MLST) were also determined (http://saureus.mlst.net/). This is 
a well established method for determining clonality in S. aureus and utilizes the sequence of seven 
house-keeping genes to determine allelic profiles [21]. Predicted transmembrane domains (TMDs) 
of proteins were determined using TMHMM v 2.0 [22].
Membrane lipid analysis
Lipid measurements were performed after a modified Bligh and Dyer extraction of the total polar 
lipids [23] and quantified using LC-MRM (multiple reaction monitoring) as described in 
supplementary material (Text S1). Three independent colonies from each strain were assessed and 
each extract was run in triplicate. Differences in the PG:L-PG ratio were assessed by student's t test 
at a significance level of P≤0.05.
TEM
Cells were prepared for TEM as described previously [5]. In brief, cells from late-exponential phase 
were fixed with 2.5% (vol/vol) glutaraldehyde and 2.0% (wt/vol) osmium tetroxide, and then 
stained with 2.0% (wt/vol) uranyl acetate. After embedding in LR White resin and cutting thin 
sections, samples were further stained with uranyl acetate and then imaged using a LEO 912AB 
microscope. The cell wall of 100 cells for each strain were measured in a blinded fashion and 
compared using the student's t test with a significance level of P≤0.05.
RESULTS AND DISCUSSION 
Clinical and laboratory S. aureus strains exposed to daptomycin
The characteristics of the S. aureus strains used in this study are shown in Tables 1 and 2. All the 
clinical pairs or series of S. aureus were obtained from patients with bloodstream infection who 
failed or had persistent infection while being treated with daptomycin. Most were complicated by 
endocarditis or other deep-seated infection (Table 1). Each pair or series includes the initial 
infecting isolate, which was daptomycin-susceptible (MIC≤1 µg/ml), and the subsequent isolate/s 
that were daptomycin-nonsusceptible after daptomycin exposure. For most strains, exposure to 
daptomycin did not change the MIC to vancomycin (Table 1 and 2). The increase in MIC to 
daptomycin for the laboratory exposed strains was equivalent to that seen for the clinical isolates, 
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with no differences observed between agr+ S. aureus (A8115) and its isogenic agr− (A8117) 
mutant strain (Table 2). In vitro selection has the advantage of assessing genetic changes specific 
to daptomycin exposure alone, but is limited by the absence of host factors and immune responses 
that may alter the evolution of daptomycin resistance. This unique collection of carefully selected 
isogenic S. aureus strains provided us with an excellent opportunity to investigate the mechanisms 
of resistance to one of our last line anti-staphylococcal antibiotics, daptomycin.
Table 2. Characteristics of the daptomycin
-exposed laboratory strains of 
Staphylococcus aureus used in this study.
doi:10.1371/journal.pone.0028316.t002
• Download: PowerPoint slide | larger image (55KB PNG) | original image (301KB TIFF) 
Whole genome sequencing of daptomycin-susceptible S. aureus parent strains
All daptomycin-susceptible parent genomes were sequenced to an average of 24-fold coverage 
(range 14- to 39-fold) and were of similar sizes, ranging from 2.72 Mb to 2.97 Mb (mean of 2.84 
Mb). The mean number of putative open reading frames was 2757 (range 2539–3066) and the 
percentage GC content was similar between strains (mean 32.72%, range 32.58%–32.84%) 
(http://www.broadinstitute.org/annotation /genome/staphylococcus_aureus_drug_resis tance/). As 
shown in Tables 1 and 2, seven of the parent strains were sequence type (ST) 5 and three were 
ST8, which are the more common MLST types in hospital-acquired S. aureus in North America [24]. 
Two parent strains were ST105, which has been less commonly reported (http://saureus.mlst.net/). 
Detailed phylogenetic analysis is shown in Fig. S1, and illustrates the high degree of genetic 
conservation between the parent strains isolated from different patients in this study.
Number and type of genetic mutations associated with daptomycin exposure
To investigate the genetic mutations associated with the in vivo or in vitro evolution of daptomycin 
resistance, all isogenic daughter strains (21 strains) were sequenced and compared to their 
daptomycin-susceptible parent strains. On average, only six coding region mutations were observed 
across the entire genome in the clinical in vivo daptomycin exposed strains (range 2–13 mutations), 
whereas only two mutations on average (range 1–4 mutations) were seen in the laboratory in vitro 
exposed pairs (Table S1). In the clinical pairs, the majority of mutations were SNPs (mean 4, range 
2–8), with an average of 2 insertions or deletions per pair. All but three SNPs led to an amino acid 
change in their respective proteins (Table S1). Mutated genes were categorized by function to 
identify themes of bacterial physiology that may contribute towards reduced susceptibility to 
daptomycin (Fig. 1). Interestingly, the most consistent mutation, which was found in all 12 strain 
pairs, was a mutation in a gene important for membrane phospholipid biosynthesis, highlighting the 
central aspect of cell membrane physiology to susceptibility to daptomycin.
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Figure 1. Percentage of daptomycin-
exposed pairs (n = 12) with a mutation in 
each functional gene category.
All daptomycin-nonsusceptible isolates had at 
least one mutation in a gene coding for 
phospholipid biosynthesis, including mprF, cls2 
or pgsA.
doi:10.1371/journal.pone.0028316.g001
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Mutations within genes associated with phospholipid biosynthesis
Daptomycin is an anionic molecule but when complexed with calcium ions, its properties and mode 
of action are analogous to cationic antimicrobial peptides [9], [25], where interaction with the 
negatively-charged cell membrane leads to membrane perturbation and cell lysis [4], [5]. The gene 
most frequently mutated in our daptomycin-resistant strains was mprF. Point mutations in this gene 
were found in all nine clinical pairs and one laboratory-derived pair (Table 3 and S1). This gene 
codes for a large membrane protein that contains 14 transmembrane domains (TMDs), and serves 
two key functions; the addition of positively charged lysine residues onto PG to form L-PG, which is 
mediated by a C-terminal lysinylation domain, and the translocation of this L-PG to the outer leaflet 
of the cytoplasmic membrane, which is mediated by the N-terminal translocation domain [9]. This 
acts to neutralize membrane charge and creates resistance to cationic peptides such as host 
immune factors and daptomycin, and highlights its importance in bacterial immune evasion and 
fitness within the host [9], [26]. It has been previously shown that mprF point mutations in 
daptomycin-nonsusceptible isolates are associated with a gain-in-function, leading to greater L-PG 
in the outer leaflet of the membrane and a further reduction in the net-negative membrane charge 
leading to electrorepulsion [26].
Table 3. Predicted protein changes in clinical- and laboratory-derived daptomycin-
nonsusceptible isolates of Staphylococcus aureus.
doi:10.1371/journal.pone.0028316.t003
• Download: PowerPoint slide | larger image (71KB PNG) | original image (207KB TIFF) 
The predicted amino acid changes associated with the 11 SNPs identified within mprF in this study 
are shown in Fig. 2A. All SNPs were independently confirmed by PCR and sequencing. Eight SNPs 
were mapped to four positions within the lysinylation and translocation domains (Fig. 2A). One SNP 
(G61V) was found within the N-terminal translocation domain only, and two SNPs were mapped to 
one position (L826F) in the C-terminal lysinylation domain only (Fig. 2A). We hypothesize that the 
latter two predicted amino acid changes may either directly enhance translocation of L-PG to the 
bacterial surface by increasing translocase activity of MprF, or enhance lysinylation of PGs leading 
to increasing pools of L-PG on the inner leaflet of the membrane [9]. Accumulation of intracellular L
-PG may stimulate translocation to the outer leaflet of the membrane in a gradient-dependent 
manner. This would, in turn, exacerbate the reduced net-negative charge of the bacterial surface, 
thus contributing to daptomycin non-susceptibility [9], [10], [26]. The importance of mutations 
within MprF to daptomycin susceptibility is also shown by the sequence of mutations in the clinical 
series (A9781–A9798). As shown in Table 1 and S1, the MIC to daptomycin increased to the 
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nonsusceptible range once the mprF mutation 
occurred in A9792 (S295L). Interestingly, the 
final isolate of the series (A9798) had a different 
mprF mutation (G61V) compared to its 
predecessor (A9792), and both strains had 
mutations in genes not found in the other. This 
suggests that multiple resistant subpopulations 
are likely to have been present rather than a 
step-wise accumulation in mutations. Finally, not 
all daptomycin-nonsusceptible mutants had mprF
mutations, particularly the laboratory-derived 
strains, suggesting that host pressures, such as 
cationic antimicrobial peptides, may influence 
MprF-mediated daptomycin resistance.
Figure 2. Phospholipid biosynthesis genes 
are integral to the development of 
reduced susceptibility to daptomycin in S. 
aureus.
(A) The predicted amino acid changes 
associated with the 11 SNPs identified within 
mprF. (B) The five mutations identified in cls2 
were mapped to four positions in the protein, 
all within the two N-terminal transmembrane 
domains. (C) Six mutations were identified in 
pgsA and were mapped to four positions in the protein, three of which were in transmembrane 
domains. The ‘A’ numbers correspond to the daptomycin-nonsusceptible isolates, and the arrows 
point to the position of the amino acid change.
doi:10.1371/journal.pone.0028316.g002
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Mutations in a second phospholipid biosynthesis gene were identified in five of the studied pairs 
(Tables 3 and S1). This gene was cardiolipin synthase (cls2), mutations of which may have been 
predicted to have a role given observations of altered gene expression in a laboratory-derived 
daptomycin-nonsusceptible strain [27]. Cardiolipin is an important anionic membrane phospholipid 
that is synthesized from the phosphatidyl moiety of two PG molecules by the membrane-bound 
enzyme, Cls [28]. Under conditions of stress, such as unfavorable growth conditions or cell-wall 
acting antibiotics, cardiolipin can accumulate up to ~25%–30% of membrane phospholipid [28]. 
Cardiolipin synthase is predicted to contain two TMDs, spanning residues 13–35 and 45–67, as well 
as two putative cardiolipin synthase domains across residues 229–256 and 407–434 (Fig. 2B). The 
four SNPs identified within Cls2 reside exclusively within the two putative TMDs at the N-terminus of 
the protein (Fig. 2B). All mutations were independently confirmed by PCR and sequencing. 
Importantly, two of the laboratory-derived daptomycin-nonsusceptible mutants (A10151 and 
A10155) from two distinct parent strains (A8115 and A5948; Tables 3 and S1), had only a single 
point mutation in cls2, both at the same position and involving the same amino acid change 
(Thr33Asn). This single point mutation in cls2 caused an increase in MIC to daptomycin from 0.5 
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µg/ml to ≥2.0 µg/ml in both pairs. No other 
gene mutations were identified in these two 
pairs based on the whole genome sequence. We 
hypothesise that mutations within the TMDs 
impair membrane localisation and function of 
Cls, resulting in altered cardiolipin synthesis. 
These changes alone, or in concert with an mprF 
mutation, which was seen in three of the clinical 
pairs (Table 3), may be important in the charge-
based repulsion of daptomycin, or may alter 
binding of daptomycin to the membrane. 
Interestingly, it has previously been shown that 
cls gene expression, as determined by 
microarray analysis, was repressed in a 
laboratory-derived daptomycin-nonsusceptible 
mutant but mutations in the gene were not 
assessed [27]. Finally, adding strength to the 
role of cls in daptomycin susceptibility, two 
recent reports have described its involvement in 
reduced susceptibility to daptomycin in clinical 
strains of Enterococcus [29], [30].
A third gene novel to daptomycin susceptibility 
and also involved in membrane phospholipid 
biosynthesis was also identified, known as CDP-
diacylglycerol-glycerol-3-phosphate 3-phosphatidyltransferase (pgsA). PgsA is important in the 
production of PG, the most abundant anionic membrane phospholipid. Interestingly, mutations in 
pgsA have recently been described to be associated with reduced susceptibility to daptomycin in 
Bacillus subtilis [31]. Our mutations were only identified in laboratory-exposed strains; however as 
shown for cls, a point mutation in pgsA alone (strain A10152) was enough to cause an increase in 
MIC of daptomycin from 0.5 µg/ml to 2 µg/ml (Tables 2 and S1). Five SNPs were mapped to three 
positions of the protein, and as seen with cls mutations, all these SNPs were within TMDs (Fig. 2C). 
One in-frame insertion was also identified (Table 3 and Fig. 2C). Our hypothesis is that these 
mutations impair PgsA function leading to reduced PG in the membrane and subsequent surface 
charge alterations. Further work is required to characterize the role of this gene in S. aureus 
susceptibility to daptomycin. The interaction and significance of mutations in these three 
phospholipid biosynthesis genes to daptomycin susceptibility is shown in figure 3.
Figure 3. Schematic of our working hypothesis for the functional effect of the observed 
mutations.
mprF mutations lead to an increase in lysinylation of phosphotidylglycerol (PG) to form L-PG, and 
an increase in translocation of this positively charged L-PG to the outer leaflet of the membrane, 
leading to electrorepulsion of daptomycin. In isolation, or in concert with mprF mutations, 
mutations in cls2 may lead to altered membrane charge or effect binding of daptomycin to the 
membrane. Finally, PgsA is important in the initial step of phospholipid biosynthesis, converting 
CDP-diacylglycerol (CDP-DG) into PG.
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Host pressure and daptomycin exposure lead to mutations across a functionally diverse 
array of genes
We observed a greater number of mutations in our clinical versus laboratory-derived pairs, 
highlighting the importance of host immune pressures on the genetic response of S. aureus to an 
antimicrobial. Apart from mutations in phospholipid biosynthesis genes, five of the clinical pairs had 
at least one mutation in a gene encoding a transcriptional regulator or a two-component signal 
transduction system (Fig. 1 and Table S1). These included walK (previously yycG), agr, stp1, tcaR 
and rsbU (sigma-B regulation), which are all important cell wall biosynthesis and/or virulence 
regulators, with the majority being reported for the first time relating to daptomycin exposure. 
Despite mutations in rpoB being initially reported with a laboratory-derived daptomycin-
nonsusceptible isolate [11], we identified only two pairs (clinical) that had mutations within rpoB 
(Table S1). Less common mutations were observed in other systems of physiological function 
including carbohydrate and amino acid metabolism, ion and small molecule transporters, and 
housekeeping genes (Fig. 1 and Table S1), demonstrating the diverse array of genes mutated 
during the in vivo evolution of daptomycin resistance. However, apart from the genes involved in 
phospholipid biosynthesis, none of the other genetic mutations were consistently observed across 
all the pairs. It is of interest though that several of the mutated genes regulate cell wall 
biosynthesis, and have also been implicated in reduced susceptibility to vancomycin [3]. 
Furthermore, many are associated with virulence regulation, and suggest that these daptomycin-
nonsuscpetible clinical isolates may have altered virulence; a hypothesis that needs further 
evaluation.
Daptomycin induces cell wall thickening and changes in membrane lipid composition
Given the frequency of mutations associated with phospholipid biosynthesis, and the presence of 
mutations in genes that regulate cell wall turnover (walK, agr, stp1), we characterized the ratio of 
cell membrane lipids (PG:L-PG ratio) and cell wall thickness in two representative clinical pairs 
(A8819/A8817 and A8796/A8799). Both these pairs have point mutations in mprF in different 
locations of the lysinylation domain (Fig. 2A). Consistent with the described physiology, the 
daptomycin-nonsusceptible daughter strain, A8817, had an increase in L-PG in the cell membrane, 
with a drop in the PG:L-PG ratio from 3.7 to 1.2 for A8819/A8817 (P<0.05). For the second pair, 
despite there being an increase in L-PG in absolute terms (PG:L-PG ratio of 3.2 to 2.5 for 
A8796/A8799), the difference was not significant (P = 0.2). It has previously been shown that 
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subtle changes in L-PG in the outer membrane leaflet can affect daptomycin susceptibility [9]. In 
the same two clinical pairs, we also observed greater cell wall thickness in both daptomycin-
nonsusceptible isolates versus their susceptible parent strains (Fig. 4), with a mean (±SD) 
thickness of 35.7 nm (±4.1) and 42.8 nm (±5.6) in the susceptible strains (A8819 and A8796, 
respectively) versus 48.1 nm (±5.9) and 53.2 nm (±7.1) in their corresponding resistant daughter 
strains (A8817 and A8799, respectively) (P<0.001 for both). Of note, the genetic mutations in both 
these pairs (Table S1) did not clearly explain the increase in cell wall thickness. Other groups have 
shown that cell wall thickness in daptomycin-nonsusceptible strains is not a consistent finding [14], 
[32], and a more recent analysis suggested that in some strains it may be due to an increase in 
wall teichoic acid [33].
Figure 4. Transmission electron 
microscopy of two clinical pairs showing a 
thickening of the cell wall in the 
daptomycin-nonsusceptible isolates.
(A) and (B) represent A8819 (daptomycin-
susceptible) and A8817 (daptomycin-
nonsusceptible), respectively. (C) and (D) 
represent A8796 (daptomycin-susceptible) and 
A8799 (daptomycin-nonsusceptible), 
respectively. P<0.001 for both.
doi:10.1371/journal.pone.0028316.g004
• Download: PowerPoint slide | larger image (1.37MB PNG) | original image (1.2MB TIFF) 
Conclusions
We have performed whole genome sequencing of the largest collection of daptomycin exposed S. 
aureus strains to date. Our data show that mutations in genes responsible for phospholipid 
biosynthesis appear important for the development of reduced susceptibility to daptomycin, more 
specifically, mutations in mprF, cls2 and pgsA. We hypothesise that mutation in each of these genes 
act similarly to reduce the net-negative charge of the cell membrane leading to electrorepulsion of 
daptomycin. They may act in isolation or in concert with each other, particularly for mutations in 
mprF and cls2 (Fig. 3). Our data also show that in vivo pressures in the setting of daptomycin 
exposure select for a range of other genetic mutations, including those involving virulence 
regulatory genes. Finally, we have shown in select clinical isolates, the functional significance of the 
observed genetic mutations by analysing changes in the cell wall and membrane lipid profiles. 
Through use of carefully selected strains and broad-based genomics, this work provides important 
insights into the mechanism of resistance to one of our last-line anti-staphylococcal antibiotics, 
daptomycin.
SUPPORTING INFORMATION 
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